Showing 4341-4350 of 5646 results for "".
- SyncThink Receives Second FDA Clearance for Mobile, Rapid Test for Concussionhttps://modernod.com/news/syncthink-receives-second-fda-clearance-for-first-mobile-rapid-test-for-concussion/2480327/SyncThink has received FDA clearance for its EYE-SYNC technology as an aid to concussion, or mild traumatic brain injury (mTBI) diagnosis. EYE-SYNC received breakthrough device designation from the FDA in 2019, following the initial clearance and commercialization of the technology plat
- Nidek Launches Retina Scan Duo 2 OCT/Fundus Camerahttps://modernod.com/news/nidek-launches-retina-scan-duotm-2-octfundus-camera/2480323/Nidek has announced the launch of the Retina Scan Duo 2, a combined OCT and fundus camera system. The Retina Scan Duo 2 incorporates new features designed to enhance screening and clinical efficiency, in addition to user-friendly features that were incorporated from the previous model.<
- Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Planhttps://modernod.com/news/orasis-pharmaceuticals-appoints-julie-speed-as-senior-vice-president-head-of-strategy-and-marketing-to-lead-commercial-growth-plan/2480321/Orasis Pharmaceuticals announced the appointment of Julie Speed as senior vice president (SVP), head of strategy and marketing. Ms. Speed brings over two decades of leadership in eye care and will be responsible for developing the brand strategy and building the marketin
- Adverum Presents Data Showing Gene Therapy Maintained Efficacy, Durability, Safety in Wet AMD Patientshttps://modernod.com/news/adverum-data-shows-gene-therapy-maintained-efficacy-durability-safety-in-wet-amd-patients/2480318/Adverum Biotechnologies announced new long-term data from the OPTIC clinical trial of ADVM-022 single, in-office intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). Safety and efficacy data f
- Ludwin Monz Stepping Down as CEO of Carl Zeiss Meditechttps://modernod.com/news/ludwin-monz-stepping-down-as-ceo-of-carl-zeiss-meditec/2480316/President and CEO of Carl Zeiss Meditec AG Ludwin Monz, PhD, announced that he will not be accepting another term in office, and will be stepping down from his postion effective December 31, 2021. The supervisory board has appointed Markus Weber, PhD, as the new President and
- Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Diabetic Retinal Disease to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meetinghttps://modernod.com/news/ocuphires-clinical-phase-2b-oral-drug-candidate-apx3330-for-diabetic-retinal-disease-to-be-featured-at-the-ois-retina-at-asrs-and-asrs-2021-annual-meeting/2480315/Ocuphire Pharma announced that its clinical-stage, novel oral Ref-1 inhibitor, APX3330, for the treatment of diabetic retinal disease will be featured at the Ophthalmology Innovation Summit (OIS) Retina@ASRS Innovation Company Showcase on October 7 in San Antonio, TX. The APX333
- Graybug Vision Reports Analysis of Data from the 6-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMDhttps://modernod.com/news/graybug-vision-reports-analysis-of-data-from-the-6-month-extension-study-of-the-altissimo-phase-2b-trial-in-wet-amd/2480304/Graybug Vision provided full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary formulation of sunitinib malate injected twice-a-year intravitreally. The ALTISSIMO trial was
- Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medicalhttps://modernod.com/news/eyevensys-enters-collaboration-with-phillips-medisize-and-minnetronix-medical/2480302/Eyevensys has entered into strategic engagements with US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop the next generation of the company’s core technology. Terms of the deal w
- RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditionshttps://modernod.com/news/rd-fund-launches-opus-genetics-with-19m-seed-funding-to-advance-gene-therapy-treatments-for-blinding-conditions/2480298/The Retinal Degeneration Fund (RD Fund), the venture arm of the Foundation Fighting Blindness, announced the launch of
- Clearside Biomedical Completes Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-completes-dosing-in-cohort-2-of-phase-12a-clinical-trial-of-cls-ax-in-wet-amd-patients/2480292/Clearside Biomedical announced completion of dosing in Cohort 2 of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a U.S.-based, multicenter